Top Markets
#1 DogBull DogBull +54.73%
#2 Siren Siren +31.33%
#3 OriginTrail OriginTrail +17.13%
#4 龙虾 (Lobster) 龙虾 (Lobster) +9.48%
#5 Yield Basis Yield Basis +9.42%
#6 Verus Coin Verus Coin +7.40%
#7 Stargate Finance Stargate Finance +7.16%
#8 Collect on Fanable Collect on Fanable +6.91%
#9 LayerZero LayerZero +6.90%
#10 COTI COTI +6.55%
Coin of the day
DogBull DogBull
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
3D Medicines Inc. 3D Medicines Inc.

3D Medicines Inc.

1244
Classificação em ações #22092
Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a... Established in 2014 and headquartered in Qingdao, China, 3D Medicines Inc. is a biopharmaceutical company dedicated to the discovery, development, and market introduction of innovative oncology drugs and therapeutic candidates. Its core mission is to address diverse cancer types, primarily serving patients in Mainland China. The company's flagship product, Envafolimab, is a PD-L1 antibody administered via subcutaneous injection. This treatment is approved for advanced solid tumors characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status in patients who have undergone previous therapies. Beyond its currently marketed drug, 3D Medicines boasts a robust development pipeline. Two significant candidates are currently undergoing Phase III clinical trials: 3D189, which targets multiple tumor indications, and 3D229 (a GAS6/AXL inhibitor), under investigation for non-small cell lung cancer, ovarian cancer, and kidney cancer. The company's Phase II pipeline includes 3D1001, designed to manage postoperative dental pain and tumor-related discomfort, and 3D1002, also aimed at oncology pain relief. Additionally, 3D185 is in Phase I clinical evaluation for locally advanced or metastatic solid tumors. Further promising candidates in earlier stages encompass 3D197 for multi-indication tumor immunotherapy, 3D011 for advanced malignant solid tumors, and 3D057 for various types of tumors.
Preço da ação
$0.38441832
Última sincronização: 2026-08-21
Valor de mercado
$94.54M
Variação (1 dia)
-12.13%
Variação (1 ano)
-62.78%
País
CN
Negociar 3D Medicines Inc. (1244)

Categoria

Healthcare
Margem Operacional de 3D Medicines Inc. (1244)
Margem Operacional em 2026 TTM: 0.00%
De acordo com os relatórios financeiros mais recentes e o preço das ações da 3D Medicines Inc., a margem operacional atual (TTM) é 0.00%. No final de 2026, a margem operacional era 0.00%.
Histórico da Margem Operacional da 3D Medicines Inc. de 2026 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
Não há dados suficientes para as datas fornecidas.
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.